Engimmune Therapeutics
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hegenheimermattweg 167a, Allschwil, Base...Website
www.engimmune.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Engimmune Therapeutics
Headquartered in Basel, Switzerland, Engimmune Therapeutics is a biotechnology company with a focus on T-cell receptor (TCR)-based therapeutics. The company was founded in 2021.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Engimmune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Engimmune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Engimmune Therapeutics recently announced quarterly report
Check out if Engimmune Therapeutics is spiking on competitors!
Check if Engimmune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Engimmune Therapeutics has new funding data
Product Launch: Get notified when Engimmune Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Engimmune Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Engimmune Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Engimmune Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Engimmune Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Engimmune Therapeutics.
Engimmune Therapeutics financials insights
Gather financial insights about Engimmune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Angel/Seed
$16.7M
Engimmune Therapeutics Tech Stack
A closer look at the technologies used by Engimmune Therapeutics
Most Recent Scoops
Executive Move
Board of Directors
Executive Move
Board of Directors
New Hire
Executive Move
Engimmune Therapeutics has announced that Lars Nieba has joined the organization as Chief Executive Officer. Previously, Nieba served as Chief Technology Officer for Nordic Nanovector.
Lateral Move
Executive Move
Funding
Engimmune Therapeutics News & Media
Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors
Leading industry expert with more than 25 years of experience in translation research in immunology BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to...Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer
Dr. Søren Mouritsen, co-founder of Engimmune, steps down as Chief Executive Officer in planned transition BASEL, Switzerland, April 19, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, today...Engimmune Therapeutics Raises CHF 15.5M in Seed Financing
Engimmune Therapeutics, a Basel, Switzerland-based biotech company developing novel T-cell receptor (TCR)-based therapeutics, raised CHF 15.5M in Seed funding. The round was led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. The company intends to use the funds to further build its pipeline, expand the research team in Switzerland and build a presence in Denmark, with […] The post Engimmune Therapeutics Raises CHF 15.5M in Seed Financing appeared first on FinSMEs.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Engimmune Therapeutics
Sign Up For FreeTo access detailed company insights
Headquartered in Basel, Switzerland, Engimmune Therapeutics is a biotechnology company with a focus on T-cell receptor (TCR)-based therapeutics. The company was founded in 2021.... Read More
